Gene: BRAF ×
Source: BEFREE ×
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs113488022
rs113488022
BRAF
0.750 GeneticVariation BEFREE Accordingly, the combination of MEK inhibitor with EGFR inhibitor was effective at shrinking tumors in mouse model of BRAF non-V600E mutant lung cancer. 29348459

2018
dbSNP: rs113488022
rs113488022
BRAF
0.750 GeneticVariation BEFREE Success of this design of clinical trials and practice was first demonstrated in EGFR inhibitor trials in lung cancer and has since been incorporated into subsequent targeted therapy trials including ALK-, ROS1-, and BRAF V600E-targeted therapies. 28786099

2017
dbSNP: rs113488022
rs113488022
BRAF
0.750 GeneticVariation BEFREE BRAF V600E is an emerging drug target in lung cancer, but the clinical significance of non-V600 BRAF mutations in lung cancer and other malignancies is less clear. 24035431

2013
dbSNP: rs113488022
rs113488022
BRAF
0.750 GeneticVariation BEFREE The incidence of BRAF mutations other than V600E is significantly higher in lung cancer than in melanoma. 21483012

2011
dbSNP: rs113488022
rs113488022
BRAF
0.750 GeneticVariation BEFREE V599E BRAF mutation was uncommon in Japanese lung cancer. 16376942

2006
dbSNP: rs121913377
rs121913377
BRAF
0.050 GeneticVariation BEFREE Accordingly, the combination of MEK inhibitor with EGFR inhibitor was effective at shrinking tumors in mouse model of BRAF non-V600E mutant lung cancer. 29348459

2018
dbSNP: rs121913377
rs121913377
BRAF
0.050 GeneticVariation BEFREE Success of this design of clinical trials and practice was first demonstrated in EGFR inhibitor trials in lung cancer and has since been incorporated into subsequent targeted therapy trials including ALK-, ROS1-, and BRAF V600E-targeted therapies. 28786099

2017
dbSNP: rs121913377
rs121913377
BRAF
0.050 GeneticVariation BEFREE BRAF V600E is an emerging drug target in lung cancer, but the clinical significance of non-V600 BRAF mutations in lung cancer and other malignancies is less clear. 24035431

2013
dbSNP: rs121913377
rs121913377
BRAF
0.050 GeneticVariation BEFREE The incidence of BRAF mutations other than V600E is significantly higher in lung cancer than in melanoma. 21483012

2011
dbSNP: rs121913377
rs121913377
BRAF
0.050 GeneticVariation BEFREE V599E BRAF mutation was uncommon in Japanese lung cancer. 16376942

2006
dbSNP: rs1225976306
rs1225976306
BRAF ; LOC105375536
0.020 GeneticVariation BEFREE To substantiate these results, an allitinib-sensitive lung cancer-derived cell line (H292) was transfected with plasmids carrying the two most common activating KRAS mutations (p.G12D and p.G12S). 26920031

2016
dbSNP: rs1225976306
rs1225976306
BRAF ; LOC105375536
0.020 GeneticVariation BEFREE Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated whether hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung carcinoma with a KRAS (G12S)-mutation. 27863474

2016
dbSNP: rs121913348
rs121913348
BRAF
0.010 GeneticVariation BEFREE Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated whether hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung carcinoma with a KRAS (G12S)-mutation. 27863474

2016
dbSNP: rs868021367
rs868021367
BRAF
0.010 GeneticVariation BEFREE Of the 13 genotypes, 4 genotypes (G464E, G596R, A598T, and G606R) had not been previously reported in lung cancer. 24297085

2014